Advances in Spinal Muscular Atrophy: Treatment, Research, and Comprehensive Management

Spinal muscular atrophy (SMA) has seen continuous advances in spinal muscular atrophy research, clinical treatment, and long-term disease management in recent years.

With the expanding use of disease-modifying therapies (DMTs) and the growing accumulation of real-world evidence, SMA care is gradually shifting from traditional supportive treatment toward precision medicine and comprehensive lifelong management centered on disease mechanisms.

HongKong DengYueMed reviews the latest advances in spinal muscular atrophy treatment, biomarker research, and integrated management strategies to support clinical practice and long-term patient care.

What Is Spinal Muscular Atrophy (SMA)? From a Motor Neuron Disease to a Multisystem Disorder

Spinal muscular atrophy (SMA) is a hereditary neuromuscular disease caused by deletion or mutation of the SMN1 gene.

The condition is characterized by progressive degeneration of anterior horn motor neurons in the spinal cord, leading to muscle weakness, muscle atrophy, and declining motor function.

Recent advances in spinal muscular atrophy research have expanded the understanding of SMA beyond a classic motor neuron disorder, revealing that it may involve multiple organ systems and broader neurological networks.

👉 At the metabolic level, studies have shown significant associations between serum copper concentration and body composition abnormalities in children with SMA, including:

• Higher copper levels associated with increased fat percentage
• Elevated fat-to-muscle ratio
• Reduced muscle mass percentage

These findings suggest that metal ion metabolism may contribute to disease-related muscle composition changes and could become a future target for nutritional and metabolic intervention.

👉 At the central nervous system level, cerebellar pathology has attracted increasing attention. Research has demonstrated:

• Progressive damage to cerebellar Purkinje cells
• Abnormal cerebellar neural circuitry
• Social and vocalization abnormalities in SMA animal models

These findings indicate that SMA may affect broader neural developmental networks beyond spinal motor neurons alone.

Latest Advances in Spinal Muscular Atrophy Treatment: A Multi-Mechanism Therapeutic Era

Current advances in spinal muscular atrophy treatment have fully entered the disease-modifying therapy era. The primary goal of these therapies is to increase SMN protein expression and improve motor neuron survival.

1. RNA Splicing Modifiers: Nusinersen Established the Foundation of DMT Therapy

Nusinersen was the first approved disease-modifying therapy for SMA. It works by modifying SMN2 pre-mRNA splicing to increase functional SMN protein production and improve motor neuron survival.

Major clinical and real-world advances in spinal muscular atrophy involving nusinersen include:

• Long-term efficacy stability
  Multiple real-world studies have shown sustained improvement or stabilization in HFMSE and RULM motor function scores, particularly in patients with SMA type 2 and type 3.
• Progressive cumulative functional improvement
  The proportion of patients achieving clinically meaningful improvement (CMI) increases with repeated dosing, suggesting cumulative and time-dependent treatment effects.
• Greater benefit from early intervention
  Younger patients and those with better baseline motor function tend to experience more significant long-term improvement, reinforcing the importance of early diagnosis and treatment.
• Manageable long-term safety profile
  Long-term studies have not identified major new safety concerns. Most adverse events remain mild to moderate, including headache and back pain.

2. Oral SMN2 Splicing Modifiers: Systemic Coverage and Long-Term Maintenance Therapy

Risdiplam is an oral SMN2 splicing modifier designed to increase SMN protein expression throughout both central and peripheral tissues.

Key characteristics include:

• Convenient oral administration
  Oral dosing avoids repeated intrathecal injections and may improve long-term treatment adherence.
• Systemic mechanism of action
  The therapy increases SMN protein levels not only in the central nervous system but also in peripheral tissues, potentially benefiting multisystem disease manifestations.
• Broad applicability across age groups
  Clinical studies have demonstrated efficacy in infants, children, adolescents, and adults with SMA.

3. Gene Replacement Therapy: Restoring SMN1 Function at the Source

Gene replacement therapy has become another major milestone in advances in spinal muscular atrophy treatment.

Onasemnogene abeparvovec delivers a functional copy of the SMN1 gene using an AAV9 viral vector as a one-time treatment strategy.

Important features include:

• Root-cause therapeutic mechanism
  The therapy directly addresses SMN1 deficiency by restoring functional gene expression.
• Strong dependence on treatment timing
  Outcomes are significantly better when treatment is administered before symptom onset or during early disease stages.
• Ongoing long-term evaluation
  Early results are promising, but long-term durability and safety continue to be monitored.

Overall, advances in spinal muscular atrophy treatment have created a multi-mechanism therapeutic landscape involving gene replacement therapy, RNA splicing modulation, and long-term maintenance treatment.

Advances in Spinal Muscular Atrophy Real-World Research: New Understanding of Long-Term Disease Management

As clinical use expands globally, real-world evidence (RWE) studies are providing deeper insight into long-term disease progression and management in SMA.

Recent studies suggest:

• Some patients continue to gain motor function over time
• Others maintain stable disease status for prolonged periods
• The nervous system may retain partial neuroplasticity
• Treatment outcomes are strongly associated with age and disease stage

Increasing evidence indicates that SMA is gradually transitioning from a rapidly progressive disorder into a chronic neuromuscular disease that may be managed over the long term.

Researchers are also paying greater attention to:

• Daily independence
• Mental health and social participation
• Long-term quality of life
• Family caregiving burden

This reflects an important shift in treatment goals—from merely slowing disease progression to improving overall functional living.

Advances in Spinal Muscular Atrophy Biomarkers and Imaging: Toward Precision Assessment and Treatment Prediction

With the development of precision medicine, advances in spinal muscular atrophy biomarker research are shifting from simply describing disease status toward predicting therapeutic response.

✅ In blood biomarker studies, baseline serum creatinine levels have been associated with improvements in motor function.

Patients with higher creatinine levels often demonstrate greater improvement in HFMSE and RULM scores, suggesting that creatinine may reflect preserved muscle reserve or residual motor function.

✅ In imaging research, quantitative spinal cord MRI studies have shown improvement in spinal cord cross-sectional area and gray matter structure in pediatric SMA patients following treatment. Adult patients, however, more commonly exhibit structural stabilization, suggesting that disease plasticity may be age-dependent.

✅ In addition, cerebrospinal fluid proteomic studies identified reductions in neuronal pentraxin 2 (NPTX2) levels after treatment, with changes correlating with motor improvement. NPTX2 may therefore emerge as a promising biomarker for monitoring treatment response in SMA.

Advances in Comprehensive SMA Management: From Drug Therapy to Multimodal Integrated Care

As advances in spinal muscular atrophy treatment continue, disease management is evolving from medication-only approaches toward integrated strategies combining pharmacologic therapy, rehabilitation, neuromodulation, and intelligent assistive technologies.

Spinal Cord Stimulation (SCS)

International studies have explored spinal cord stimulation (SCS) in adult SMA patients for the first time. Findings demonstrated:

• Increased motor neuron firing frequency
• Approximately 180% improvement in muscle strength
• Better gait quality and walking endurance
• Partial persistence of benefit even after stimulation cessation

These findings provide new perspectives for restoring neural circuit function in SMA.

HAL-Assisted Rehabilitation Therapy

Japanese real-world studies have investigated Hybrid Assistive Limb (HAL) therapy combined with nusinersen and conventional rehabilitation.

Results showed:

• Greater HFMSE improvement
• Enhanced upper limb function
• Improved walking ability

This suggests that multimodal treatment strategies may further optimize long-term outcomes.

Multidisciplinary Rehabilitation Remains Essential

Recent reviews emphasize that even in the DMT era, multidisciplinary rehabilitation remains fundamental for long-term SMA management, including:

• Respiratory management
• Nutritional support
• Orthopedic and skeletal care
• Exercise and physical therapy
• Psychological support
• Social reintegration

Emerging technologies such as artificial intelligence, robotic-assisted rehabilitation, and virtual reality may further drive the future of precision rehabilitation in SMA.

Future Directions in SMA: Why Early Diagnosis and Long-Term Precision Management Matter

One of the most important advances in spinal muscular atrophy care is the recognition that early diagnosis and early treatment are critical for improving long-term outcomes.

Motor neuron damage in SMA is often irreversible. During the early disease stage, patients still retain more functional neurons, making early intervention more effective in preserving motor function and slowing disease progression.

Newborn screening programs are now expanding worldwide, allowing some patients to receive disease-modifying therapy before symptom onset and significantly altering the natural course of SMA.

Long-term follow-up studies consistently show that patients treated earlier often achieve better outcomes in:

• Motor performance
• Independent living ability
• Long-term quality of life

Meanwhile, future advances in spinal muscular atrophy research are expected to focus on:

• More precise biomarker systems
• Combination and sequential therapy strategies
• Novel gene-editing and RNA technologies
• AI-assisted rehabilitation and intelligent disease management
• Long-term quality-of-life research

In recent years, China has continued to advance in rare disease diagnosis and treatment systems, neuromuscular disease management, and access to innovative therapies, providing international patients with more options for treatment and long-term follow-up care.

Conclusion

The field of spinal muscular atrophy is undergoing rapid transformation.

From disease mechanism research and disease-modifying therapies to real-world evidence, precision biomarkers, and comprehensive rehabilitation management, advances in spinal muscular atrophy are driving SMA care toward a more personalized, precise, and long-term management era.

As innovative therapies continue to emerge, drug accessibility and global medical collaboration will become increasingly important.

As a global pharmaceutical distribution platform, DengYueMed will continue to focus on international access to innovative SMA therapies while exploring cross-border healthcare and international patient support services to help provide broader treatment opportunities for patients worldwide.

FAQ about Advances in Spinal Muscular Atrophy